Biblio
.
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.
Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS. Blood Adv. 2023.
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022.
Transplant in AML with measurable residual disease: proceed or defer?. Hematology Am Soc Hematol Educ Program. 2022;2022(1):528-533.
. Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future. Br J Haematol. 2020;191(4):568-572.
. Bone marrow transplantation in the United Kingdom - past, present and future. Br J Haematol. 2020;191(4):612-616.
. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018.
Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?. Curr Opin Hematol. 2018.
.